Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepatyrix vs Havrix/Typherix/Typhim Vi in healthy adults
NCT00197249Phase 3Completed
- Sponsor
- GSK
- Start
- May 2002
- Primary completion
- Jun 2003
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, open-label trial of Hepatyrix in hepatitis A (HAV) and typhoid fever (4 arms), sponsored by GSK. Primary endpoints: Anti-Vi seropositivity rates at 1 month and Anti-HAV seropositivity rates at 1 month. Started May 2002; status: completed.
02
Drugs
Hepatyrix
03
Conditions
hepatitis A (HAV)typhoid fever
Beyond the preview
Go deeper on NCT00197249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00197249.